Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()

OBJECTIVE: To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity and type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Transl Endocrinol
Main Authors: Van Gaal, Luc, Souhami, Elisabeth, Zhou, Tianyue, Aronson, Ronnie
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685032/
https://ncbi.nlm.nih.gov/pubmed/29159080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcte.2014.03.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados